YHR131W-A Antibody

What is YHR131W-A and why are antibodies against it used in research?

YHR131W-A is a putative uncharacterized protein in Saccharomyces cerevisiae (baker's yeast, strain ATCC 204508/S288c). Antibodies against this protein are primarily used in fundamental research to study yeast cell biology, protein expression patterns, and cellular processes in S. cerevisiae. These antibodies serve as important tools for detecting, localizing, and quantifying the YHR131W-A protein in experimental systems .

The significance of studying YHR131W-A lies in advancing our understanding of yeast biology, which often serves as a model system for eukaryotic cellular processes. Research using this antibody contributes to the broader field of proteomics and functional genomics in model organisms.

How can I validate the specificity of a YHR131W-A antibody?

Proper validation of antibody specificity is critical for ensuring reliable experimental results. For YHR131W-A antibody validation, you should employ multiple complementary approaches:

• Knockout Controls: Generate YHR131W-A knockout yeast strains and compare antibody binding between wild-type and knockout samples. This is considered the gold standard for validation .

• Western Blot Analysis: Run wild-type and knockout lysates side-by-side. A specific antibody will show band(s) at the expected molecular weight only in the wild-type sample .

• Epitope Mapping: Identify the specific region of YHR131W-A that the antibody recognizes. This can be done using peptide arrays with overlapping residues, similar to the approach used for epitope mapping in other studies .

• Cross-Reactivity Testing: Test the antibody against lysates from other related yeast species to evaluate potential cross-reactivity .

Recent studies have shown that knockout validation is superior to other control types, particularly for Western blot and immunofluorescence applications, with an average of 12 publications per protein target including data from antibodies that failed to recognize their intended targets .

What are the recommended experimental conditions for using YHR131W-A antibody in Western blot applications?

For optimal results in Western blot applications using YHR131W-A antibody, follow these methodological recommendations:

Table 1: Recommended Western Blot Protocol for YHR131W-A Antibody

Always include a positive control (wild-type yeast lysate) and negative control (YHR131W-A knockout lysate or unrelated yeast species) to validate specificity in each experiment .

How can I optimize immunofluorescence protocols using YHR131W-A antibody?

Optimizing immunofluorescence with YHR131W-A antibody requires careful attention to fixation, permeabilization, and antibody incubation conditions:

• Cell Preparation:

  • Culture S. cerevisiae to mid-log phase (OD₆₀₀ = 0.6-0.8)

  • Fix cells using 4% paraformaldehyde for 30 minutes at room temperature

  • Treat with Zymolyase to create spheroplasts (10 μg/ml, 30 minutes at 30°C)

• Antibody Incubation:

  • Block with 3% BSA in PBS for 1 hour

  • Incubate with YHR131W-A antibody at 1:100-1:500 dilution overnight at 4°C

  • Wash 3x with PBS

  • Apply fluorophore-conjugated secondary antibody (1:1000) for 1 hour at room temperature in the dark

• Controls and Validation:

  • Always include wild-type and knockout strains as controls

  • Consider co-staining with established organelle markers to determine protein localization

  • Use DAPI for nuclear counterstaining

Recent findings from YCharOS indicate that knockout cell lines provide superior controls for immunofluorescence imaging compared to other control types .

How can I determine if YHR131W-A antibody recognizes specific post-translational modifications of the protein?

Investigating post-translational modifications (PTMs) recognized by YHR131W-A antibody requires sophisticated techniques:

• Parallel Analysis with PTM-Specific Treatments:

  • Compare antibody recognition in samples treated with phosphatases, deglycosylation enzymes, or other PTM-removing enzymes

  • Observe changes in band patterns or signal intensity that might indicate PTM recognition

• Mass Spectrometry Validation:

  • Perform immunoprecipitation using the YHR131W-A antibody

  • Analyze immunoprecipitated proteins by mass spectrometry to identify PTMs present on captured proteins

  • Compare with total proteome analysis to determine enrichment of specific PTM forms

• Peptide Competition Assays:

  • Synthesize peptides with and without specific PTMs

  • Pre-incubate antibody with these peptides before application to samples

  • Reduction in signal with specific PTM-containing peptides indicates PTM recognition

These approaches are consistent with advanced antibody characterization methods used in scientific research for determining antibody specificity and epitope recognition patterns .

What bioinformatic approaches can predict epitopes for designing new YHR131W-A antibodies?

Modern computational approaches can greatly enhance YHR131W-A antibody design through epitope prediction:

• Structure-Based Epitope Prediction:

  • Use AlphaFold-Multimer or similar AI tools to predict the 3D structure of YHR131W-A

  • Apply RosettaAntibodyDesign (RAbD) framework to sample diverse sequence, structure, and binding space

  • Identify surface-exposed regions with high predicted antigenicity

• Machine Learning Approaches:

  • Implement active learning strategies similar to those used in antibody-antigen binding prediction

  • Start with small labeled datasets and iteratively expand through targeted experimental validation

  • This approach has been shown to reduce the number of required antigen variants by up to 35%

• Epitope Mapping from Existing Antibodies:

  • Use peptide arrays with overlapping residues to map linear epitopes recognized by existing antibodies

  • Identify immunogenic regions that might serve as targets for new antibody development

Recent advances in AI-based antibody design, such as IsAb2.0, demonstrate that computational optimization can significantly improve antibody binding affinity through accurate modeling of antibody-antigen complexes and in silico optimization .

How can I address non-specific binding issues with YHR131W-A antibody?

Non-specific binding is a common challenge when working with antibodies. To mitigate this issue with YHR131W-A antibody:

• Optimize Blocking Conditions:

  • Test different blocking agents (BSA, non-fat milk, normal serum)

  • Extend blocking time to 2-3 hours at room temperature

  • Include 0.1-0.3% Triton X-100 or Tween-20 in blocking buffer to reduce hydrophobic interactions

• Antibody Dilution Series:

  • Perform a dilution series (1:100 to 1:10,000) to determine optimal antibody concentration

  • Higher dilutions often reduce non-specific binding while maintaining specific signal

• Pre-adsorption Protocol:

  • Incubate diluted antibody with lysate from YHR131W-A knockout yeast

  • Allow 2 hours at room temperature or overnight at 4°C

  • Centrifuge (14,000 × g, 10 minutes) and use the supernatant for experiments

• Additional Washes:

  • Increase wash duration and number of washes

  • Use higher salt concentration in wash buffer (up to 500 mM NaCl) to disrupt weak non-specific interactions

The YCharOS initiative has demonstrated that proper antibody characterization is critical for research reproducibility, with studies showing that approximately 50% of commercial antibodies fail to meet basic characterization standards .

What are the best practices for storing and maintaining YHR131W-A antibody to preserve activity?

Proper storage and handling are essential for maintaining antibody functionality:

Table 2: Storage and Handling Recommendations for YHR131W-A Antibody

For reconstituted lyophilized antibodies, it's advisable to add sterile PBS with carrier protein (0.1% BSA) to achieve the desired concentration. When stored under the recommended conditions, the YHR131W-A antibody should maintain activity for at least 12 months .

Research has demonstrated that antibody stability and performance can vary significantly based on storage conditions, with appropriate buffer composition and temperature being critical factors for preserving functionality .

How can YHR131W-A antibody be used in comparative proteomics across different yeast strains?

YHR131W-A antibody can serve as a valuable tool in comparative proteomics through several methodological approaches:

• Quantitative Western Blot Analysis:

  • Compare YHR131W-A expression levels across different yeast strains and growth conditions

  • Use densitometry analysis normalized to housekeeping proteins

  • Apply statistical methods to determine significant differences in expression patterns

• Immunoprecipitation Coupled with Mass Spectrometry:

  • Use YHR131W-A antibody to immunoprecipitate the target protein and its interacting partners

  • Analyze strain-specific interaction networks through LC-MS/MS

  • Identify differential protein-protein interactions that may reflect functional adaptations

• Chromatin Immunoprecipitation (ChIP) Analysis:

  • If YHR131W-A has nuclear functions, use ChIP to investigate DNA-binding patterns

  • Compare genomic binding sites across strains using ChIP-seq

  • Correlate binding with transcriptional changes measured by RNA-seq

This approach aligns with advanced proteomics methods used in modern research, where antibodies serve as key tools for investigating protein function in complex biological systems .

What machine learning approaches can improve YHR131W-A antibody characterization?

Advanced machine learning methods are increasingly valuable for antibody characterization:

• Binding Affinity Prediction:

  • Implement active learning algorithms similar to those used for antibody-antigen binding prediction

  • Start with small datasets and iteratively expand through targeted experimental validation

  • This approach has been shown to reduce the number of required experiments by up to 35%

• Epitope Mapping and Analysis:

  • Apply neural network models to predict antibody-antigen binding interfaces

  • Compare predicted epitopes with experimentally determined ones to validate and improve the model

  • Use these predictions to design improved antibodies with enhanced specificity

• Cross-Reactivity Assessment:

  • Employ similarity search algorithms similar to those used in PLAbDab (Patent and Literature Antibody Database)

  • Analyze CDR sequences and structures to predict potential cross-reactivity with other yeast proteins

  • This approach can identify antibodies with similar binding properties across different targets

Recent research demonstrates that incorporating AI methods like those used in IsAb2.0 can significantly improve antibody design processes, allowing for accurate prediction of mutations that enhance binding affinity and specificity .